Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 265, P. 155729 - 155729
Published: Nov. 19, 2024
Language: Английский
Cells, Journal Year: 2024, Volume and Issue: 13(15), P. 1245 - 1245
Published: July 24, 2024
Circular RNAs (circRNAs) are cardinal players in numerous physiological and pathological processes. CircRNAs play dual roles as tumor suppressors oncogenes different oncological contexts, including hepatocellular carcinoma (HCC). Their significantly impact the disease at all stages, initiation, development, progression, invasion, metastasis, addition to response treatment. In this review, we discuss biogenesis regulatory functional of circRNAs, well circRNA-protein-mRNA ternary complex formation, elucidating intricate pathways tuned by circRNAs modulate gene expression cellular processes through a comprehensive literature search, silico bioinformatics analysis. With particular focus on interplay between epigenetics, HCC pathology, article sets stage for further exploration novel investigational theranostic agents dynamic realm HCC.
Language: Английский
Citations
9
Nanoscale Advances, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Extracellular vesicles (EVs) are emerging tools in cancer diagnosis, prognosis and therapeutics.
Language: Английский
Citations
1
Translational Oncology, Journal Year: 2025, Volume and Issue: 54, P. 102329 - 102329
Published: Feb. 26, 2025
Language: Английский
Citations
0
Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 47
Published: March 13, 2025
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide, characterized by its complex pathogenesis and poor therapeutic outcomes. Despite recent advances in targeted molecular therapies, immune checkpoint inhibitors (ICIs), radiotherapy, conventional chemotherapy, five-year survival rate for this neoplasm remains dismally low. The progress nanotechnology has revolutionized cancer treatment years. These provide unprecedented opportunities to overcome current limitations different modalities. This review provides a comprehensive analysis how interfaces with tumor microenvironment (TIME) HCC can present new frontier interventions HCC. We critically overview latest developments nanoparticle-based delivery systems various drugs also other antitumor agents like thermal therapy radiotherapy. highlight unique ability nanoparticles modulate immunosuppressive (TME) enhance efficacy. Furthermore, we analyze emerging strategies that exploit nanoformulations biological barriers drug bioavailability treatment.
Language: Английский
Citations
0
Translational Oncology, Journal Year: 2025, Volume and Issue: 55, P. 102365 - 102365
Published: March 24, 2025
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: April 2, 2025
Maternally expressed gene 3 (MEG3), a long non-coding RNA, plays pivotal role in various biological processes, including tumorigenesis. Aberrant expression of MEG3 has been implicated several cancers, genitourinary malignancies. This comprehensive review explores the multifaceted functions context cancers through unravelling molecular mechanisms underlying influence on cellular proliferation, apoptosis, invasion, and metastasis. Additionally, we discuss potential clinical implications as biomarker therapeutic target cancers. By unraveling intricate these this aims to contribute development novel strategies for diagnosis treatment
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: April 3, 2025
Cancer is a complex and highly lethal disease marked by unchecked cell proliferation, aggressive behavior, strong tendency to metastasize. Despite significant advancements in cancer diagnosis treatment, challenges such as early detection difficulties, drug resistance, adverse effects of radiotherapy or chemotherapy continue threaten patient survival. MicroRNAs (miRNAs) have emerged critical regulators biology, with miR-506 being extensively studied recognized for its tumor-suppressive across multiple types. This review examines the regulatory mechanisms common cancers, focusing on role competing endogenous RNA (ceRNA) network apoptosis, migration. We also discuss potential therapeutic target overcoming resistance treatment. Overall, these insights underscore promise developing novel therapies.
Language: Английский
Citations
0
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: April 17, 2025
Abstract Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by limited therapeutic options and poor prognosis. Despite advancements in precision oncology, conventional chemotherapy remains the cornerstone of TNBC treatment, often accompanied debilitating side effects suboptimal outcomes. This review presents a comprehensive analysis clinical trials on targeted therapies, aiming to establish novel, evidence-based treatment strategy exclusively leveraging molecularly agents. By integrating patient-specific genetic profiles with responses observed across various trial phases, this approach seeks optimize efficacy while minimizing toxicity. The proposed therapy combinations hold significant potential revolutionize offering paradigm shift toward medicine improved patient
Language: Английский
Citations
0
Cancer Control, Journal Year: 2024, Volume and Issue: 31
Published: Jan. 1, 2024
Circulating tumor markers with satisfactory sensitivity and specificity play crucial roles in cancer diagnosis therapy. This prospective study aimed to evaluate the potential of circulating lncRNAs as biomarkers for hepatocellular carcinoma (HCC).
Language: Английский
Citations
3
Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 263, P. 155638 - 155638
Published: Oct. 5, 2024
Language: Английский
Citations
3